当前位置： SCI文献检索 > Applied Health Economics and Health Policy期刊下所有文献 > Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact.

Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact.

Abstract：

:We conducted a scoping review with the objective of synthesizing available literature and mapping what designs and methods have been used to evaluate health insurance reforms in sub-Saharan Africa. We systematically searched for scientific and grey literature in English and French published between 1980 and 2017 using a combination of three key concepts: "Insurance" and "Impact evaluation" and "sub-Saharan Africa". The search led to the inclusion of 66 articles with half of the studies pertaining to the evaluation of National Health Insurance schemes, especially the Ghanaian one, and one quarter pertaining to Community-Based Health Insurance and Mutual Health Organization schemes. Sixty-one out of the 66 studies (92%) included were quantitative studies, while only five (8%) were defined as mixed methods. Most studies included applied an observational design (n = 37; 56%), followed by a quasi-experimental (n = 27; 41%) design; only two studies (3%) applied an experimental design. The findings of our scoping review are in line with the observation emerging from prior reviews focused on content in pointing at the fact that evidence on the impact of health insurance is still relatively weak as it is derived primarily from studies relying on observational designs. Our review did identify an increase in the use of quasi-experimental designs in more recent studies, suggesting that we could observe a broadening and deepening of the evidence base on health insurance in Africa over the next few years.

journal_name

Appl Health Econ Health Policy

journal_title

Applied health economics and health policy

authors

Degroote S,Ridde V,De Allegri M

doi

10.1007/s40258-019-00499-y

subject

Has Abstract

pub_date

2020-12-01 00:00:00

pages

825-840

issue

6

eissn

1175-5652

issn

1179-1896

pii

10.1007/s40258-019-00499-y

journal_volume

18

pub_type

杂志文章,评审

相关文献

Applied Health Economics and Health Policy文献大全
  • Inclusion of compliance and persistence in economic models: past, present and future.

    abstract：:Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/BF03261872

    authors： Kadambi A,Leipold RJ,Kansal AR,Sorensen S,Getsios D

    更新日期：2012-11-01 00:00:00

  • Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

    abstract：BACKGROUND:It is estimated that annually 300 000 cases of rotavirus-induced gastroenteritis (RVGE) occur in children aged up to 5 years in France. A two-dose vaccine against rotavirus infection (RIX4414; Rotarix, GlaxoSmithKline), has been shown to be highly effective against severe RVGE. OBJECTIVE:This study evaluate...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/BF03256134

    authors： Standaert B,Parez N,Tehard B,Colin X,Detournay B

    更新日期：2008-01-01 00:00:00

  • Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.

    abstract：:In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effectiveness. To set ceiling prices, IQWiG uses the following decision rule: the incremental cost-effectiveness ratio (ICER) of a n...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11586640-000000000-00000

    authors： Gandjour A

    更新日期：2011-03-01 00:00:00

  • The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance.

    abstract：:Memokath-051 is a thermo-expandable, nickel-titanium alloy spiral stent used to treat ureteric obstruction resulting from malignant or benign strictures. The National Institute for Health and Care Excellence (NICE) selected Memokath-051 for evaluation. The company, PNN Medical, claimed Memokath-051 has clinical superi...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-018-0389-3

    authors： Eaton Turner E,Jenks M,McCool R,Marshall C,Millar L,Wood H,Peel A,Craig J,Sims AJ

    更新日期：2018-08-01 00:00:00

  • Listening to the decision makers: sustainability of PBMA in Alberta.

    abstract：BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/00148365-200403030-00005

    authors： Mitton C,Patten S,Donaldson C

    更新日期：2004-01-01 00:00:00

  • Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy: results from a survey.

    abstract：BACKGROUND:The management of the large patient population in Italy receiving long-term oral anticoagulation therapy (OAT) poses organizational challenges that are traditionally approached with a centralized procedure, relying on hospital-based clinics and/or GPs. However, the availability of near-patient testing device...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11313890-000000000-00000

    authors： Pradelli L,Iannazzo S,Zaniolo O,Botrugno P

    更新日期：2010-01-01 00:00:00

  • Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.

    abstract：BACKGROUND:There is limited understanding of the health economic implications of cervical screening with human papillomavirus (HPV)-16/18 genotyping. OBJECTIVE:The aim of this study was to evaluate the cost effectiveness of cervical cancer primary screening with a HPV-16/18 genotyping test which simultaneously detects...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-014-0135-4

    authors： Huh WK,Williams E,Huang J,Bramley T,Poulios N

    更新日期：2015-02-01 00:00:00

  • New anti-rebate legislation in South Korea.

    abstract：:The South Korean Government recently announced a reform in the drug anti-rebate law, with the purpose of eradicating pervasive, unethical, and illegal rebate practices in pharmaceutical marketing. The main objective of this reform is to have the ability to bring criminal charges against doctors and pharmacists for rec...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-013-0029-x

    authors： Yu SY,Yang BM,Kim JH

    更新日期：2013-08-01 00:00:00

  • Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

    abstract：BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-013-0050-0

    authors： Zeidler J,Mahlich J,Greiner W,Heres S

    更新日期：2013-10-01 00:00:00

  • A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

    abstract：BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-015-0183-4

    authors： Campbell JR,Sasitharan T,Marra F

    更新日期：2015-08-01 00:00:00

  • Cost of Medicare for All: Review of the Estimates.

    abstract：:This paper critically evaluates the estimates of the cost of Medicare for All (M4A) in the USA. Six studies that estimate the 1-year total cost of M4A in the USA are reviewed. These studies find that M4A would increase national health spending by as much as 16.9% or decrease it by 20.0%, representing a range of estima...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-021-00636-6

    authors： Nyman JA

    更新日期：2021-01-25 00:00:00

  • Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System.

    abstract：BACKGROUND:Early awareness and alert systems have been established in many countries but evidence on their ability to accurately prioritize new medicines (for early assessment) is limited. OBJECTIVE:The purpose of this study was to assess whether the Swedish Early Awareness and Alert System identified and prioritized ...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0434-2

    authors： Eriksson I,von Euler M,Malmström RE,Godman B,Wettermark B

    更新日期：2019-02-01 00:00:00

  • Socioeconomic Disparities in Unmet Need for Student Mental Health Services in Higher Education.

    abstract：BACKGROUND:Mental health problems are highly prevalent among college students in many countries. However, evidence suggests that many at-risk students do not receive professional help. OBJECTIVE:We aimed to understand which students are most likely to have unmet need for mental health services. Given increasing and wi...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00529-9

    authors： Cullinan J,Walsh S,Flannery D

    更新日期：2020-04-01 00:00:00

  • Reducing smoking prevalence in Australian prisons: a review of policy options.

    abstract：:Smoking of tobacco products is a major public health challenge in prison settings in most countries. Although tobacco use was tolerated by custodial authorities for many decades, the overwhelming evidence of the adverse public health effects of tobacco on both the smokers and those in the vicinity of exhaled or passiv...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：

    authors： Awofeso N

    更新日期：2002-01-01 00:00:00

  • Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.

    abstract：BACKGROUND:South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea. METHODS:We pull...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00547-7

    authors： Lee HJ,Han E,Kim H

    更新日期：2020-08-01 00:00:00

  • EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing: a NICE medical technology guidance.

    abstract：:A routine part of the process for developing National Institute for Health and Care Excellence (NICE) medical technologies guidance is a submission of clinical and economic evidence by the technology manufacturer. The Birmingham and Brunel Consortium External Assessment Centre (EAC; a consortium of the University of B...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-014-0117-6

    authors： Higgins A,Glover M,Yang Y,Bayliss S,Meads C,Lord J

    更新日期：2014-10-01 00:00:00

  • Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

    abstract：OBJECTIVES:The objective of this study was to construct an early economic evaluation for acalabrutinib for relapsed chronic lymphocytic leukaemia (CLL) to assist early reimbursement decision making. Scenarios were assessed to find the relative impact of critical parameters on incremental costs and quality-adjusted life...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-019-00496-1

    authors： Vreman RA,Geenen JW,Hövels AM,Goettsch WG,Leufkens HGM,Al MJ

    更新日期：2019-12-01 00:00:00

  • The influence of bonus payments to doctors on hospital revenue: results of a quasi-experimental study.

    abstract：:There is wide consensus that the ways in which providers are reimbursed by third parties will affect their behaviour and, hence, the efficient use of limited resources and the performance of health systems. However, there seems to be little evidence on how payment to hospital-based doctors affects hospital performance...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：

    authors： Liu X,Mills A

    更新日期：2003-01-01 00:00:00

  • Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

    abstract：BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the exte...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-012-0002-0

    authors： McEwan P,Kim R,Yuan Y

    更新日期：2013-02-01 00:00:00

  • Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.

    abstract：BACKGROUND:little is known about the economics of acquiring and processing the more than 14 million units of red blood cells used annually in the US. OBJECTIVE:to determine the average price paid by hospitals to suppliers for a unit of red blood cells and to identify cost variations by region and facility type and siz...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.2165/11530740-000000000-00000

    authors： Toner RW,Pizzi L,Leas B,Ballas SK,Quigley A,Goldfarb NI

    更新日期：2011-01-01 00:00:00

  • Does Insurance Status Influence a Patient's Hospital Charge?

    abstract：BACKGROUND:There is obscurity regarding how US hospitals determine patients' charges. Whether insurance status influences a patient's hospital charge has not been explored. OBJECTIVE:The objective of this study was to determine whether hospitals charge patients differently based on their insurance status. METHODS:Thi...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-017-0308-z

    authors： Woodworth L,Romano PS,Holmes JF

    更新日期：2017-06-01 00:00:00

  • Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert® MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis.

    abstract：BACKGROUND:The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0397-3

    authors： Pallas SW,Courey M,Hy C,Killam WP,Warren D,Moore B

    更新日期：2018-08-01 00:00:00

  • Cost data assessment in multinational economic evaluations: some theory and review of published studies.

    abstract：:This article reviews the concept of costing, and how cost data have been considered and reported in recent multinational economic evaluations. It appears that current practice frequently does not comply with microeconomic foundations and standards for good practice. A number of studies fail to indicate the year of cos...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：

    authors： Halliday RG,Darba J

    更新日期：2003-01-01 00:00:00

  • Informing disinvestment through cost-effectiveness modelling: is lack of data a surmountable barrier?

    abstract：:The mandatory nature of recommendations made by the National Institute for Health and Clinical Excellence (NICE) in the UK has highlighted inherent difficulties in the process of disinvestment in existing technologies to fund NICE-approved technologies. A lack of evidence on candidate technologies means that the proce...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/BF03256137

    authors： Karnon J,Carlton J,Czoski-Murray C,Smith K

    更新日期：2009-01-01 00:00:00

  • Propensity-score matching in economic analyses: comparison with regression models, instrumental variables, residual inclusion, differences-in-differences, and decomposition methods.

    abstract：:This paper examines the use of propensity score matching in economic analyses of observational data. Several excellent papers have previously reviewed practical aspects of propensity score estimation and other aspects of the propensity score literature. The purpose of this paper is to compare the conceptual foundation...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-013-0075-4

    authors： Crown WH

    更新日期：2014-02-01 00:00:00

  • A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.

    abstract：:This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative an...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/s40258-014-0150-5

    authors： Hu S,Zhang Y,He J,Du L,Xu M,Xie C,Peng Y,Wang L

    更新日期：2015-08-01 00:00:00

  • The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations.

    abstract：BACKGROUND:Immunization rates for human papillomavirus (HPV) infections remain low among teenagers despite strong evidence of the effectiveness of vaccines. Physician recommendations of the vaccine are far from universal. Several states have enacted policies that mandate HPV vaccination or distribute educational materi...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-016-0225-6

    authors： Moghtaderi A,Adams S

    更新日期：2016-06-01 00:00:00

  • Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review.

    abstract：OBJECTIVES:The objective of the present work was to assess the level of evidence in economic evaluations of percutaneous left atrial appendage closure devices, and to test the complementarity of three different tools for assessing the quality of economic evaluations. METHODS:We conducted a systematic review of article...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/s40258-018-0429-z

    authors： Nédellec E,Pineau J,Prognon P,Martelli N

    更新日期：2018-12-01 00:00:00

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    abstract：:The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章,评审

    doi：10.1007/BF03256162

    authors： Sermet C,Andrieu V,Godman B,Van Ganse E,Haycox A,Reynier JP

    更新日期：2010-01-01 00:00:00

  • Financial risk of the biotech industry versus the pharmaceutical industry.

    abstract：:The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...

    journal_title：Applied health economics and health policy

    pub_type： 杂志文章

    doi：10.1007/BF03256149

    authors： Golec J,Vernon JA

    更新日期：2009-01-01 00:00:00